Synthesis and Structure–Activity Relationships of (Aryloxy)quinazoline Ureas as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors
作者:Antonio Garofalo、Amaury Farce、Séverine Ravez、Amélie Lemoine、Perrine Six、Philippe Chavatte、Laurence Goossens、Patrick Depreux
DOI:10.1021/jm2013453
日期:2012.2.9
site. This model was used to direct the synthesis of new compounds. A series of N-(aromatic)-N′-4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}urea were identified as potent and selective inhibitors of the tyrosine kinase activity of VEGFR-2 (fetal liver kinase 1, kinase insert domain-containing receptor). An efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution
在我们不断寻找治疗增生性疾病的药物中,喹唑啉衍生物被合成并作为上皮生长因子受体和血管内皮生长因子受体2(VEGFR-2)酪氨酸激酶抑制剂进行药理评价。进行了定量构效关系分析,以合理化构效关系并预测两种蛋白质激酶的抑制剂结合谱可能基于铅化合物对接至ATP结合位点的相似程度。该模型用于指导新化合物的合成。一系列N-(芳香族)-N'-4-[(6,7-二甲氧基喹唑啉-4-基)氧基]苯基}脲被确定为VEGFR-2酪氨酸激酶活性的有效和选择性抑制剂(胎儿肝激酶1,含激酶插入结构域的受体) 。开发了一种有效的途径,该途径使得能够合成多种类似物,并在模板的多个位置上进行取代。与ATP竞争的二芳基脲的取代,提供了几种具有低纳摩尔抑制VEGFR-2酶活性的类似物。在本文中,我们描述了该系列的合成,结构-活性关系以及药理学表征。